Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment

Colorectal Disease

Volumn 18, Issue 7, 2016, Pages 667-675

  de Groof, E J ^a   Sahami, S ^a   Lucas, C ^a   Ponsioen, C Y ^a   Bemelman, W A ^a   Buskens, C J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti TNF; Crohn's perianal fistula; seton

Indexed keywords

ADALIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR;

ANUS FISTULA; COHORT ANALYSIS; COMPARATIVE STUDY; CROHN DISEASE; DRAIN; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SETON; STATISTICAL ANALYSIS; SURGICAL DRAINAGE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84978732044     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.13311     Document Type: Review

References (67)

1. Russel MG, Dorant E, Volovics A et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998; 41: 33–40.
2. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980; 21: 525–7.
3. Vigano C, Losco A, Caprioli F, Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with crohn's disease. Inflamm Bowel Dis 2011; 17: 2102–8.
4. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
5. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7.
6. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001; 15: 1639–46.
7. Ardizzone S, Colombo E, Maconi G et al. Infliximab in treatment of Crohn's disease: the Milan experience. Dig Liver Dis 2002; 34: 411–8.
8. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 771–5.
9. Orlando A, Colombo E, Kohn A et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577–83.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
11. Viswanathan M, Ansari MT, Berkman ND et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. 2008.
12. Chung W, Ko D, Sun C et al. Outcomes of anal fistula surgery in patients with inflammatory bowel disease. Am J Surg 2010; 199: 609–13.
13. Galis-Rozen E, Tulchinsky H, Rosen A et al. Long-term outcome of loose seton for complex anal fistula: a two-centre study of patients with and without Crohn's disease. Colorectal Dis 2010; 12: 358–62.
14. Higashi D, Futami K, Egawa Y et al. Infliximab treatment for anal fistula in patients with Crohn's disease. Anticancer Res 2009; 29: 927–33.
15. Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn's disease. Dis Colon Rectum 2005; 48: 459–63.
16. Buchanan GN, Owen HA, Torkington J et al. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg 2004; 91: 476–80.
17. Takesue Y, Ohge H, Yokoyama T et al. Long-term results of seton drainage on complex anal fistulae in patients with Crohn's disease. J Gastroenterol 2002; 37: 912–5.
18. Shinozaki M, Koganei K, Fukushima T. Simultaneous anus and bowel operation is preferable for anal fistula in Crohn's disease. J Gastroenterol 2002; 37: 611–6.
19. Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn's disease. Dis Colon Rectum 1997; 40: 443–50.
20. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in-ano in Crohn's disease. Results of aggressive surgical treatment. Dis Colon Rectum 1991; 34: 378–84.
21. Morrison JG, Gathright JB Jr, Ray JE et al. Surgical management of anorectal fistulas in Crohn's disease. Dis Colon Rectum 1989; 32: 492–6.
22. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–33.
23. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
24. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829–38.
25. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98–103.
26. Uchino M, Ikeuchi H, Bando T et al. Long-term efficacy of infliximab maintenance therapy for perianal Crohn's disease. World J Gastroenterol 2011; 17: 1174–9.
27. Sciaudone G, Di SC, Limongelli P et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg 2010; 53: 299–304.
28. Gaertner WB, Decanini A, Mellgren A et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007; 50: 1754–60.
29. Guidi L, Ratto C, Semeraro S et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008; 12: 111–7.
30. Bouguen G, Siproudhis L, Gizard E et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol 2013; 11: 975–81.
31. Dewint P, Hansen BE, Verhey E et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014; 63: 292–9.
32. Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn's disease. Colorectal Dis 2013; 15: 210–6.
33. Duff S, Sagar PM, Rao M et al. Infliximab and surgical treatment of complex anal Crohn's disease. Colorectal Dis 2012; 14: 972–6.
34. El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn's fistulas. Colorectal Dis 2012; 14: 1217–23.
35. Fortea-Ormaechea JI, Gonzalez-Lama Y, Casis B et al. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. Gastroenterol Hepatol 2011; 34: 443–8.
36. Karmiris K, Bielen D, Vanbeckevoort D et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011; 9: 130–6.
37. Savoye-Collet C, Savoye G, Koning E, Dacher JN, Lerebours E. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis 2011; 17: 1751–8.
38. Echarri A, Castro J, Barreiro M et al. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis 2010; 4: 654–60.
39. Gligorijevic V, Spasic N, Bojic D et al. The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn's disease. Acta Chir Iugosl 2010; 57: 89–95.
40. Miheller P, Lakatos PL, Horvath G et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe–a Hungarian nationwide observational study. BMC Gastroenterol 2009; 9: 66.
41. Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther 2009; 30: 757–66.
42. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416–23.
43. Tougeron D, Savoye G, Savoye-Collet C et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009; 54: 1746–52.
44. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009; 24: 1252–7.
45. Lopez PN, Mendoza JL, Taxonera C et al. Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study. Rev Esp Enferm Dig 2008; 100: 676–81.
46. Spradlin NM, Wise PE, Herline AJ et al. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am J Gastroenterol 2008; 103: 2527–35.
47. Hinojosa J, Gomollon F, Garcia S et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409–18.
48. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837–41.
49. Ardizzone S, Maconi G, Colombo E et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004; 10: 91–6.
50. Luna-Chadid M, Perez Calle JL, Mendoza JL et al. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig 2004; 96: 379–81.
51. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol 2004; 99: 82–8.
52. Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004; 19: 295–301.
53. Bell SJ, Halligan S, Windsor AC et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 17: 387–93.
54. Topstad DR, Panaccione R, Heine JA et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577–83.
55. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol 2002; 97: 2022–5.
56. Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95: 3490–7.
57. Castano-Milla C, Chaparro M, Saro C et al. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015; 49: 34–40.
58. Yang BL, Chen YG, Gu YF et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World J Gastroenterol 2015; 21: 2475–82.
59. Kotze PG, de Albuquerque IC, Moreira AL et al. Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study. Arq Gastroenterol 2014; 51: 284–9.
60. Van AG, Dignass A, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4: 63–101.
61. Paul S, Del TE, Marotte H et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568–76.
62. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542–53.
63. Sands BE, Blank MA, Diamond RH, Barrett JP, van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006; 23: 1127–36.
64. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862–9.
65. Yassin NA, Askari A, Warusavitarne J et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Aliment Pharmacol Ther 2014; 40: 741–9.
66. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711–21.
67. de Groof EJ, Buskens CJ, Ponsioen CY et al. Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. Trials 2015; 16: 366.